Mezzion Pharmaceuticals, Inc
- Biotech or pharma, therapeutic R&D
Mezzion is a late-stage rare disease pharmaceutical company developing the first treatment for the approximately 70,000 patients living with single ventricle congenital heart disease. Peak annual sales are projected at $2.4 billion, with an estimated net present value (NPV) of $13B.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}